OBJECTIVE: We aimed to examine the association of APOE ε genotype with MRI markers of cerebrovascular disease (CVD): white matter hyperintensities, brain infarcts, and cerebral microbleeds. METHODS: We performed a systematic review and meta-analysis of 42 cross-sectional or longitudinal studies identified in PubMed from 1966 to June 2012 (n = 29,965). This included unpublished data from 3 population-based studies: 3C-Dijon, Framingham Heart Study, and Sydney Memory and Ageing Study. When necessary, authors were contacted to provide effect estimates for the meta-analysis. RESULTS: APOE ε4 carrier status and APOE ε44 genotype were associated with increasing white matter hyperintensity burden (sample size-weighted z score meta-analysis [meta]-p = 0.0034 and 0.0030) and presence of cerebral microbleeds (meta odds ratio [OR] = 1.24, 95% confidence interval [CI] [1.07, 1.43], p = 0.004, and 1.87 [1.26, 2.78], p = 0.002), especially lobar. APOE ε2 carrier status was associated with increasing white matter hyperintensity load (z score meta-p = 0.00053) and risk of brain infarct (meta OR = 1.41[1.09, 1.81], p = 0.008). CONCLUSIONS: APOE ε4 and APOE ε2 were associated with increasing burden in MRI markers for both hemorrhagic and ischemic CVD. While the association of APOE ε4 with an increased burden of CVD could be partly contributing to the relationship between APOE ε4 and AD, APOE ε2 was associated with MRI markers of CVD in the opposite direction compared to AD.
OBJECTIVE: We aimed to examine the association of APOE ε genotype with MRI markers of cerebrovascular disease (CVD): white matter hyperintensities, brain infarcts, and cerebral microbleeds. METHODS: We performed a systematic review and meta-analysis of 42 cross-sectional or longitudinal studies identified in PubMed from 1966 to June 2012 (n = 29,965). This included unpublished data from 3 population-based studies: 3C-Dijon, Framingham Heart Study, and Sydney Memory and Ageing Study. When necessary, authors were contacted to provide effect estimates for the meta-analysis. RESULTS:APOE ε4 carrier status and APOE ε44 genotype were associated with increasing white matter hyperintensity burden (sample size-weighted z score meta-analysis [meta]-p = 0.0034 and 0.0030) and presence of cerebral microbleeds (meta odds ratio [OR] = 1.24, 95% confidence interval [CI] [1.07, 1.43], p = 0.004, and 1.87 [1.26, 2.78], p = 0.002), especially lobar. APOE ε2 carrier status was associated with increasing white matter hyperintensity load (z score meta-p = 0.00053) and risk of brain infarct (meta OR = 1.41[1.09, 1.81], p = 0.008). CONCLUSIONS:APOE ε4 and APOE ε2 were associated with increasing burden in MRI markers for both hemorrhagic and ischemic CVD. While the association of APOE ε4 with an increased burden of CVD could be partly contributing to the relationship between APOE ε4 and AD, APOE ε2 was associated with MRI markers of CVD in the opposite direction compared to AD.
Authors: Tom Jeerakathil; Philip A Wolf; Alexa Beiser; John K Hald; Rhoda Au; Carlos S Kase; Joseph M Massaro; Charles DeCarli Journal: Stroke Date: 2004-05-20 Impact factor: 7.914
Authors: R Schmidt; H Schmidt; F Fazekas; M Schumacher; K Niederkorn; P Kapeller; V Weinrauch; G M Kostner Journal: Stroke Date: 1997-05 Impact factor: 7.914
Authors: E H Corder; A M Saunders; N J Risch; W J Strittmatter; D E Schmechel; P C Gaskell; J B Rimmler; P A Locke; P M Conneally; K E Schmader Journal: Nat Genet Date: 1994-06 Impact factor: 38.330
Authors: Frank-Erik de Leeuw; Florence Richard; Jan Cees de Groot; Cornelia M van Duijn; Albert Hofman; Jan Van Gijn; Monique M B Breteler Journal: Stroke Date: 2004-04-01 Impact factor: 7.914
Authors: L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn Journal: JAMA Date: 1997 Oct 22-29 Impact factor: 56.272
Authors: Nancy S Green; Monica Bhatia; Erica Y Griffith; Mahvish Qureshi; Courtney Briamonte; Mirko Savone; Stephen Sands; Margaret T Lee; Angela Lignelli; Adam M Brickman Journal: Biol Blood Marrow Transplant Date: 2017-01-09 Impact factor: 5.742
Authors: Sarah C Conner; Laurent Benayoun; Jayandra J Himali; Stephanie L Adams; Qiong Yang; Charles DeCarli; Jan K Blusztajn; Alexa Beiser; Sudha Seshadri; Ivana Delalle Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Costantino Iadecola; Kristine Yaffe; José Biller; Lisa C Bratzke; Frank M Faraci; Philip B Gorelick; Martha Gulati; Hooman Kamel; David S Knopman; Lenore J Launer; Jane S Saczynski; Sudha Seshadri; Adina Zeki Al Hazzouri Journal: Hypertension Date: 2016-10-10 Impact factor: 10.190
Authors: Dana R Jorgensen; C Elizabeth Shaaban; Clayton A Wiley; Peter J Gianaros; Joseph Mettenburg; Caterina Rosano Journal: Am J Physiol Heart Circ Physiol Date: 2018-02-02 Impact factor: 4.733
Authors: Nicholette D Palmer Allred; Laura M Raffield; Joycelyn C Hardy; Fang-Chi Hsu; Jasmin Divers; Jianzhao Xu; S Carrie Smith; Christina E Hugenschmidt; Benjamin C Wagner; Christopher T Whitlow; Kaycee M Sink; Joseph A Maldjian; Jeff D Williamson; Donald W Bowden; Barry I Freedman Journal: Diabetes Care Date: 2016-10-04 Impact factor: 19.112
Authors: Abigail Livny; Ramit Ravona-Springer; Anthony Heymann; Rachel Priess; Tammar Kushnir; Galia Tsarfaty; Leeron Rabinov; Reut Moran; Hadass Hoffman; Itzik Cooper; Lior Greenbaum; Jeremy Silverman; Mary Sano; Sterling C Johnson; Barbara B Bendlin; Michal Schnaider Beeri Journal: Diabetes Care Date: 2016-04-08 Impact factor: 19.112